Record of past volcanic eruptions — and potential hazards to health — revealed by low water levels at dwindling local tap source.
- Joint 118th Annual Cordilleran/72nd Annual Rocky Mountain Section Meeting - 2022
Argonne’s educational programs and outreach offers a number of different avenues and opportunities for students to expand their STEM identities and begin to pursue STEM careers.
Victor M. Zavala, professor at the University of Wisconsin-Madison and a computational mathematician in the Mathematics and Computer Science Division at Argonne National Laboratory, is developing scalable algorithms and software to handle the nation’s energy infrastructure challenges.
Jung, a member of the Computing and Computational Sciences Directorate at ORNL, is using his fellowship to develop essential tools of multiscale models for universal materials. He is interested in modeling materials using computational science to help develop new technology for new materials.
Fifty years ago, in 1972, the Brookhaven Linac Isotope Producer (BLIP) began operation. It was the world’s first facility to use high-energy particle beams to produce radioisotopes that are rare, new, or commercially unavailable. Since then, BLIP’s isotopes have been used for a variety of purposes—chief among them, the diagnosis and treatment of disease.
- DOE/US Department of Energy
Methane – the main component of natural gas – is the latest greenhouse gas targeted by climate science researchers. UT Professor Annette Summers Engel is the principal investigator for a multi-institutional team that received a $2.91 million grant from the National Science Foundation (NSF) to study methane emissions in coastal wetlands, which play an important role in climate change.
The U.S. Department of Energy’s Oak Ridge National Laboratory has provided hydropower operators with new data to better prepare for extreme weather events and shifts in seasonal energy demands caused by climate change.
New research from PNNL sheds light on how crystals form using atomic force microscopy.
- Science Advances
An experimental drug to fight aggressive brain cancer has proved so successful in the first trial on humans that University of South Australia scientists will fast-track the second stage. The development provides a glimmer of hope for glioblastoma patients, who face a survival time of only 12 to 18 months after diagnosis.
- Aucentra Therapeutics